AGIO AGIOS PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AGIOS PHARMACEUTICALS INC reported revenue of $44.7M (up 259.3% from a year earlier), net income of −$101M and diluted EPS of −$1.69; over the last four quarters revenue was $98.3M and net income −$412M; for the fiscal year ended December 2025 revenue was $54.0M, up 48.0% on the year before.

AGIO annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $54.0M, gross profit n/a, operating income −$472M, net income −$413M (margin -764.4%), EPS −$7.12
• Fiscal year ended Dec 2024: revenue $36.5M, gross profit n/a, operating income −$426M, net income $674M (margin 1846.7%), EPS $11.64
• Fiscal year ended Dec 2023: revenue $26.8M, gross profit n/a, operating income −$391M, net income −$352M (margin -1312.3%), EPS −$6.33
• Fiscal year ended Dec 2022: revenue $14.2M, gross profit n/a, operating income −$389M, net income −$232M (margin -1629.2%), EPS −$4.23
• Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$378M, net income $1.61B (margin n/a), EPS $26.55

AGIO quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $44.7M (up 259.3% year over year), net income −$101M, EPS −$1.69
• Quarter ended Mar 31, 2026: revenue $20.7M (up 137.7% year over year), net income −$99.1M, EPS −$1.69
• Quarter ended Dec 31, 2025 (from the annual report): revenue $20.0M (up 86.1% year over year), net income −$108M, EPS −$1.86
• Quarter ended Sep 30, 2025: revenue $12.9M (up 43.7% year over year), net income −$103M, EPS −$1.78
• Quarter ended Jun 30, 2025: revenue $12.5M (up 44.6% year over year), net income −$112M, EPS −$1.93
• Quarter ended Mar 31, 2025: revenue $8.73M (up 6.6% year over year), net income −$89.3M, EPS −$1.55
• Quarter ended Dec 31, 2024 (from the annual report): revenue $10.7M (up 51.1% year over year), net income −$96.2M, EPS −$1.44
• Quarter ended Sep 30, 2024: revenue $8.96M (up 21.2% year over year), net income $948M, EPS $16.22
• Quarter ended Jun 30, 2024: revenue $8.62M (up 28.4% year over year), net income −$96.1M, EPS −$1.69
• Quarter ended Mar 31, 2024: revenue $8.19M (up 46.0% year over year), net income −$81.5M, EPS −$1.45
• Quarter ended Dec 31, 2023 (from the annual report): revenue $7.10M (up 64.8% year over year), net income −$95.9M, EPS −$1.71
• Quarter ended Sep 30, 2023: revenue $7.40M (up 110.4% year over year), net income −$91.3M, EPS −$1.64
• Quarter ended Jun 30, 2023: revenue $6.71M (up 20.2% year over year), net income −$83.8M, EPS −$1.51
• Quarter ended Mar 31, 2023: revenue $5.61M (up 574.2% year over year), net income −$81.0M, EPS −$1.47
• Quarter ended Dec 31, 2022 (from the annual report): revenue $4.31M, net income $36.3M, EPS $0.68
• Quarter ended Sep 30, 2022: revenue $3.52M, net income −$81.7M, EPS −$1.49
• Quarter ended Jun 30, 2022: revenue $5.58M, net income −$91.8M, EPS −$1.68
• Quarter ended Mar 31, 2022: revenue $832K, net income −$94.8M, EPS −$1.74
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$94.3M, EPS −$1.74
• Quarter ended Sep 30, 2021: revenue $0, net income −$88.8M, EPS −$1.56

AGIO cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$373M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$390M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$296M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$309M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$407M, share buybacks n/a

AGIO balance sheet

• Jun 30, 2026: cash $99.6M, total assets $1.11B, total liabilities $82.4M, shareholders' equity $1.03B
• Mar 31, 2026: cash $114M, total assets $1.18B, total liabilities $75.9M, shareholders' equity $1.11B
• Dec 31, 2025: cash $89.1M, total assets $1.30B, total liabilities $104M, shareholders' equity $1.19B
• Sep 30, 2025: cash $92.7M, total assets $1.39B, total liabilities $101M, shareholders' equity $1.28B
• Jun 30, 2025: cash $80.9M, total assets $1.47B, total liabilities $102M, shareholders' equity $1.37B
• Mar 31, 2025: cash $79.0M, total assets $1.56B, total liabilities $89.0M, shareholders' equity $1.47B
• Dec 31, 2024: cash $76.2M, total assets $1.66B, total liabilities $122M, shareholders' equity $1.54B
• Sep 30, 2024: cash $254M, total assets $1.79B, total liabilities $165M, shareholders' equity $1.63B

What is AGIO's revenue?

AGIOS PHARMACEUTICALS INC reported $98.3M of revenue over its last four quarters, through June 30, 2026.

Is AGIO profitable?

No. AGIOS PHARMACEUTICALS INC lost $412M over the last four quarters.

What is AGIO's EPS?

Diluted earnings per share over the last four quarters were −$7.02; −$1.69 in the latest quarter.

AGIO ownership and insider trades · All stocks